Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic a…
$154.19+7.68%
报价 2026-11-06
市值
$6.2B
EV
$7.76B
PE (TTM)
–
预期 PE
–
52 周区间距高点 -20.4%
$105.76$193.61
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| BLTEBelite Bio, Inc | $6.2B | +7.7% | – | 0% | – | – | – | |
| ORKAOruka Therapeutics, Inc. | $6.81B | +7.1% | – | 0% | – | – | – | |
| CGONCG Oncology, Inc. Common stock | $6.74B | +17.3% | +378.6% | -102.2% | – | – | – | |
| IONSIonis Pharmaceuticals, Inc. | $6.55B | +1.6% | -1.6% | 98.3% | – | 3.1x | – | |
| IMVTImmunovant, Inc. | $6.31B | +7.5% | -37.1% | 0% | – | – | – | |
| KODKodiak Sciences Inc. | $6.24B | +9.1% | +1783.3% | 0% | – | – | – | |
| LGNDLigand Pharmaceuticals, Inc. | $6.12B | +2.4% | +8.0% | 97.5% | 31.8x | 21.8x | 124.3x | |
| MIRMMirum Pharmaceuticals, Inc. | $6.09B | +0.2% | +30.9% | 81.7% | – | – | – | |
| SRRKScholar Rock Holding Corporation | $5.72B | +3.2% | +3100.0% | 0% | – | – | – | |
| 同行中位数 | – | – | +30.9% | 0% | 31.8x | 12.4x | 124.3x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。